Skip to main content
Log in

Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The diffuse sclerosing (DSV) and tall cell (TCV) variants are considered aggressive subtypes of papillary thyroid cancer (PTC) for which data are limited.

Methods

The Surveillance, Epidemiology, and End Results (SEER) database (1988–2008) was used to compare the incidence and clinical/pathologic characteristics of DSV and TCV with classic PTC. Prognostic factors associated with survival were analyzed by chi-square test, analysis of variance, log rank test, and Cox multivariate regression.

Results

There were 261 DSV, 573 TCV, and 42,904 PTC patients. Compared to a 60.8% increase in classic PTC incidence, DSV and TCV incidence increased by 126% (P trend = 0.052) and 158% (P trend = 0.002), respectively. Aggressive variants were associated with higher rates of extrathyroidal extension, multifocality, and nodal and distant metastasis (all P < 0.001) compared to classic PTC. Nodal metastasis was more likely with DSV (72.2% vs. 66.8% TCV vs. 56.3% PTC, P < 0.001); distant metastasis was most common with TCV (11.1% vs. 7.3% DSV vs. 4.3% PTC, P < 0.001). After adjustment, DSV [hazard ratio (HR) 1.8, P = 0.007] and TCV (HR 1.9, P < 0.001) histologies were associated with significantly reduced survival (5-year overall: 87.5% DSV, 80.6% TCV vs. 93.5% PTC, P < 0.001). Tumor size independently predicted worse prognosis for TCV (HR 1.29, P < 0.001) but not DSV patients. Thyroid surgery and radioiodine improved survival of DSV and TCV patients (all P < 0.05). Patients with aggressive variants who received external-beam radiotherapy did not experience improved survival.

Conclusions

DSV and TCV are rare, increasing in incidence, and have a worse prognosis than classic PTC. Patients with these variants should be treated aggressively with thyroidectomy and radioiodine, regardless of tumor size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–14.

    Article  Google Scholar 

  2. Clark OH. Thyroid cancer and lymph node metastases. J Surg Oncol. 2011;103:615–8.

    Article  PubMed  Google Scholar 

  3. Carling T, Ocal I, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31:916–23.

    Article  PubMed  Google Scholar 

  4. Khanafshar E, Lloyd RV. The spectrum of papillary thyroid carcinoma variants. Adv Anat Pathol. 2011;18:90–7.

    Article  PubMed  Google Scholar 

  5. Patel KN, Shaha AR. Poorly differentiated and anaplstic thyroid cancer. Cancer Control. 2006;13:119–28.

    PubMed  Google Scholar 

  6. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2010;33:1052–9.

    Article  PubMed  Google Scholar 

  7. Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. 2011;21:383–9.

    Article  PubMed  Google Scholar 

  8. Lam A, Lo C, Lam K. Papillary carcinoma of thyroid: a 30-year clinicopathological review of the histological variants. Endocr Pathol. 2005;16:323–30.

    Article  PubMed  Google Scholar 

  9. Morris LGT, Myssiorek D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg. 2010;200:454–61.

    Article  PubMed  Google Scholar 

  10. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol. 2004;86:44–54.

    Article  PubMed  Google Scholar 

  11. Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid. 2008;18:1179–81.

    Article  PubMed  CAS  Google Scholar 

  12. Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007;38:212–9.

    Article  PubMed  Google Scholar 

  13. Terry JH, John SAS, Karkowski FJ, et al. Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg. 1994;168:459–61.

    Article  PubMed  CAS  Google Scholar 

  14. Fujimoto Y, Obara T, Ito Y, Kodama T, Aiba M, Yamaguchi K. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Clinical importance, surgical treatment and follow-up study. Cancer. 1990;66:2306–12.

    Article  PubMed  CAS  Google Scholar 

  15. Carangiu ML. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol. 1989;13:1041–9.

    Article  Google Scholar 

  16. Wu PS, Leslie PJ, McLaren KM, Toft AD. Diffuse sclerosing papillary carcinoma of thyroid: a wolf in sheep’s clothing. Clin Endocrinol (Oxf). 1989;31:535–40.

    Article  CAS  Google Scholar 

  17. McElvanna K, McCusker G, Stirling I. Diffuse sclerosing variant of papillary thyroid carcinoma—a rare cause of goitre in a young patient. Ulster Med J .2007;76:113–4.

    PubMed  Google Scholar 

  18. Falvo L, Giacomelli L, D’Andrea V, Marzullo A, Guerriero G, De Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg. 2006;72:438–44.

    PubMed  Google Scholar 

  19. Morris LGT, Shaha AR, Tuttle RM, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20:153–8.

    Article  PubMed  Google Scholar 

  20. Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17:655–61.

    Article  PubMed  Google Scholar 

  21. Chow SM, Chan JK, Law SC, et al. Diffuse sclerosing variant of papillary thyroid carcinoma—clinical features and outcome. Eur J Surg Oncol. 2003;29:446–9.

    Article  PubMed  Google Scholar 

  22. National Cancer Institute. Overview of the surveillance epidemiology and end results program. http://seer.about.gov/about. Accessed 4 Nov 2011.

  23. Akslen LA, Varhaug JE. Thyroid carcinoma with mixed tall-cell and columnar-cell features. Am J Clin Pathol. 1990;94:442–5.

    PubMed  CAS  Google Scholar 

  24. Pilotti S, Collini P, Manzari A. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol. 1995;82:740–53.

    Google Scholar 

  25. Wenig BM, Thompson LDR, Adair CF, Shmookler B, Heffess CS. Thyroid papillary carcinoma of columnar cell type. Cancer. 1998;82:740–53.

    Article  PubMed  CAS  Google Scholar 

  26. National Cancer Institute. Staging information for thyroid cancer. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page3. Accessed 4 Nov 2011.

  27. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery. 2010;148:1147–53.

    Article  PubMed  Google Scholar 

  28. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.

    Article  PubMed  CAS  Google Scholar 

  29. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–91.

    Article  PubMed  Google Scholar 

  30. Hodgson N, Button J, Solorzano C. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11:1093–7.

    Article  PubMed  Google Scholar 

  31. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231–6.

    Article  PubMed  Google Scholar 

  32. Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope. 2008;118:32–8.

    Article  PubMed  Google Scholar 

  33. Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88:1902–8.

    Article  PubMed  CAS  Google Scholar 

  34. Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol. 2007;20:779–87.

    Article  PubMed  CAS  Google Scholar 

  35. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies muc1 as an independent prognostic marker. Cancer Res. 2004;64:3780–9.

    Article  PubMed  CAS  Google Scholar 

  36. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216–22.

    Article  PubMed  Google Scholar 

  37. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol. 1992;23:1395–401.

    Article  PubMed  CAS  Google Scholar 

  38. Koo JS, Hong S, Park CS. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid. 2009;19:1225–31.

    Article  PubMed  Google Scholar 

  39. Thompson L, Wieneke J, Heffess C. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol. 2005;16:331–48.

    Article  PubMed  Google Scholar 

  40. Brown RL. Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol. 2008;35:298–308.

    Article  PubMed  Google Scholar 

  41. Elaraj DM, Sturgeon C. Adequate surgery for papillary thyroid cancer. Surgeon. 2009;7:286–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Julie A. Sosa MD, MA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kazaure, H.S., Roman, S.A. & Sosa, J.A. Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients. Ann Surg Oncol 19, 1874–1880 (2012). https://doi.org/10.1245/s10434-011-2129-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-2129-x

Keywords

Navigation